Artimplant interim report January 1

STOCKHOLM, Sweden, Aug. 29, 2003 (PRIMEZONE) -- Artimplant (Other OTC:APLTF)

- Consolidated net sales January-June 2003 reached SEK 14,7 million (SEK 13,1 million)

- The loss after taxes was SEK 10,9 million (SEK 28,2 million loss). The reduced loss was a result of the company's restructuring program.

- Earnings per share for the period was SEK - 0,45

- Artimplant commenced shipment of ArtelonTM Augmentation Device ACL

- 3-year results from the ArtelonTM Spacer CMC-I pilot study show that patients remain painless and stable

- 1-year results confirm that accelerated rehabilitation with Artelon Augmentation Device ACL is possible

Developments after the 6 month period

- In July Artimplant filed for FDA approval of ArtelonTM Surgical Suture

- In August Artimplant received CE-certificate for ArtelonTM Spacer CMC-I



 Forthcoming financial reports:
 January-September 2003 report:
 November 7, 2003
 Release of year end results:
 February 17, 2004

Financial reports are available at www.artimplant.se at the same time that they're distributed to the media.

This information was brought to you by Waymaker http://www.waymaker.net

The full report is available for download:

Artimplant interim report January 1 - June 30, 2003